#$%^&*AU2015271995A120160121.pdf#####ABSTRACT Compositions comprising crystalline apixaban particles having a D9 0 equal to or less than 89 tm, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.